Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma 4-year EFS(confidenceinterval ...
A simple and reproducible test is still needed to identify in newly diagnosed stage A CLL patients, those patients with a higher risk of progressive disease. Toward this end, we prospectively ...
Please provide your email address to receive an email when new articles are posted on . Patients with chronic lymphocytic leukemia who had soluble CD23 doubling times of less than one year had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results